Skip to content
DataLookout
Menu

NCT07918079

Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Percentage of Participants with No Nausea (VAS < 5 mm) During the 120-504 Hour Window After ADC Administration
Timeframe: 120 to 504 hours (Days 6-21) after ADC administration

Secondary (6)

Percentage of Participants with No Significant Nausea (VAS < 25 mm) During the 120-504 Hour Window
Percentage of Participants with No Vomiting During the 120-504 Hour Window
Complete Response (CR) Rate During the 120-504 Hour Window
Complete Protection (CP) Rate During the 120-504 Hour Window
Total Control (TC) Rate During the 120-504 Hour Window
Show 1 moreShow less
Antiemetic Efficacy Across Time Windows: No Nausea, No Significant Nausea, No Vomiting, CR, CP, TC, and Rescue Medication Rates

Arms and interventions

Standard (No Extended NEPA)Active comparator

Standard antiemetic regimen consisting of netupitant/palonosetron (NEPA), dexamethasone, and olanzapine administered on Days 1-4 (Day 5: observation only). No extended NEPA dosing is given from Day 6 through Day 21.

Extended NEPA (3 Boosts)Experimental

Standard antiemetic regimen (NEPA + dexamethasone + olanzapine) on Days 1-4, plus one additional NEPA capsule (netupitant 300 mg/palonosetron 0.5 mg, PO) on each of Days 6, 11, and 16.

Extended NEPA (2 Boosts)Experimental

Standard antiemetic regimen (NEPA + dexamethasone + olanzapine) on Days 1-4, plus one additional NEPA capsule (netupitant 300 mg/palonosetron 0.5 mg, PO) on each of Days 6 and 13.

Drugs: Netupitant and Palonosetron, Dexamethasone, Olanzapine 5 Mg ORAL TABLET